title: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers.
abstract: The pharmacokinetics and biochemical efficacy of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide (I) were evaluated in healthy male volunteers after single and multiple oral administration. The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, 50 and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively. The drug disappeared from the systemic circulation with half-lives (t1/2) of 4.7-7.1 h. The mean values of the area under the curve (AUC0-24) and Cmax increased linearly in a dose-dependent manner. After multiple oral administration of (I) (10 mg/d) for 7 days, Cmax and AUC increased slightly during administration, however, there were no significant differences between day 4 and day 7. Although there were large intersubject differences in the 24 h plasma levels after each dosing, no accumulation of (I) occurred after 7 days dosing. Serum 5-alpha-dihydrotestosterone (DHT) was markedly reduced at all dose levels. The mean serum levels of DHT at 24 h post-dosing decreased to 27-42% of that before dosing. On the other hand, the serum testosterone (T) did not change significantly. After multiple administration of (I), serum DHT was significantly reduced and remained suppressed for up to 7 days after the final dosing.
authors.affiliation: Central Research Laboratories, Banyu Pharmaceutical Co Ltd, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ohtawa
authors.forename: H
authors.initials: H
authors.lastname: Morikawa
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000328:Adult; D000736:Androstenes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D001378:Azasteroids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D013196:Dihydrotestosterone / Q000097:blood*; D004311:Double-Blind Method; D018120:Finasteride; D006801:Humans; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000097:blood*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000736:Androstenes; D001378:Azasteroids; D013196:Dihydrotestosterone; D013739:Testosterone; D018120:Finasteride